Somatostatin receptor 2 (SSTR2) is expressed by many tumor types including the majority of NB tumors, with expression in clinical samples ranging from 77 to 100% depending on the method of detection [8–12], and there is a negative correlation between SSTR2 expression and clinical risk [10]. This evidence concerns the gene SSTR2 and neoplasm.